Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Masayuki Jimbo is active.

Publication


Featured researches published by Masayuki Jimbo.


Bioorganic & Medicinal Chemistry | 1998

Chemical modification of β-glucocerebrosidase inhibitor N-octyl-β-valienamine: synthesis and biological evaluation of N-alkanoyl and N-alkyl derivatives

Seiichiro Ogawa; Yuko Kobayashi; Kazuya Kabayama; Masayuki Jimbo; Jin-ichi Inokuchi

Several N-alkanoyl 4a-d and N-alkyl derivatives 5a-g of the potent beta-glucocerebrosidase inhibitor N-octyl beta-valienamine (3) were synthesized in order to elucidate a role of hydrophobic portion in the inhibitory action. Although the former lacked inhibitory potency, the latter were strong beta-glucocerebrosidase inhibitors (cf. N-decyl-N-octyl-beta-valienamine 5d: Ki 6.6 x 10(-8) M). Furthermore, when being prescribed into mouse-derived B16 melanoma cells, N-butyl-N-octyl-beta-valienamine 5a and 5d were shown to change the amount of GlcCer and GM3, which suggests that they are possibly introduced into cells and influence glycolipids biosynthesis.


Bioorganic & Medicinal Chemistry | 1998

Synthesis and evaluation of morpholino- and pyrrolidinosphingolipids as inhibitors of glucosylceramide synthase

Tsuyoshi Miura; Tetsuya Kajimoto; Masayuki Jimbo; Kiwamu Yamagishi; Jin-Chi Inokuchi; Chi-Huey Wong

This paper describes the new synthesis and evaluation of some morpholino- and pyrrolidinosphingolipids and mimics as inhibitors of glucosylceramide synthase. It was found that the pyrrolidino derivatives are generally more active than the morpholino derivatives and the best one was shown to be a nanomolar inhibitor.


European Journal of Pharmacology | 2003

A synthetic ceramide analog ameliorates spatial cognition deficit and stimulates biosynthesis of brain gangliosides in rats with cerebral ischemia

Kiwamu Yamagishi; Kenichi Mishima; Yusuke Ohgami; Katsunori Iwasaki; Masayuki Jimbo; Hiroyuki Masuda; Yasuyuki Igarashi; Jin-ichi Inokuchi; Michihiro Fujiwara

A synthetic ceramide analog, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (L-PDMP) upregulates ganglioside biosynthesis in several cell lines. In cultured cortical neurons, neurotrophic effects of L-PDMP on neurite outgrowth and synaptic activity were demonstrated. In addition, it was found that L-PDMP could ameliorate the spatial cognition deficit in rats with ischemia. To elucidate this effect, we evaluated the effect of L-PDMP on brain ganglioside biosynthesis and its therapeutic efficacy against spatial cognition deficit in rats made ischemic. Rats were trained for 2 weeks, using an 8-arm radial maze task, and then forebrain ischemia was induced. L-PDMP was injected i.p. at 40 mg/kg twice a day starting from day 1 or 3 after ischemia induction for 6 or 4 days, respectively. The first study showed significantly reduced spatial cognition deficit at 12 h after the final drug administration, and L-PDMP tended to attenuate apoptosis in hippocampal CA1. To examine the effect of L-PDMP on brain ganglioside biosynthesis, N-[3H]acetyl-D-mannosamine was infused into the lateral ventricle via an injection cannula at 12 h after the final drug administration. After 4 h, the brain gangliosides were purified and analyzed. Upregulation of ganglioside biosynthesis by L-PDMP was observed on days 3 and 5 after ischemia. These results are an indication that L-PDMP may ameliorate spatial cognition deficit by upregulating ganglioside biosynthesis in ischemic brain.


Bioorganic & Medicinal Chemistry Letters | 1997

Synthesis and biological evaluation of four stereoisomers of PDMP-analogue, N-(2-decylamino-3-hydroxy-3-phenylprop-1-yl)-β-valienamine, and related compounds

Seiichiro Ogawa; Tamami Mito; Eiichi Taiji; Masayuki Jimbo; Kiwamu Yamagishi; Jin-ichi Inokuchi

Abstract All stereoisomers with regard to C-1 and 2 of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) analogue containing unsaturated (β-valienamine) and saturated 5a-carba-β- d -glucopyranosylamine (β-validamine) residues in place of morpholine moiety were synthesized. Although PDMP is a potent and specific glucosylceramide synthase inhibitor, the former valienamine analogues (4a-d) have been shown to be strong glucocerebrosidase inhibitors ( IC 50 3–7 ∗x 10 −7 M). The latter validamine analogues (5a-d) were also moderate glucocerebrosidase inhibitors ( IC 50 5–20 ∗x 10 −6 M). A series of compounds synthesized lacked an inhibitory potency against the glucosyltransferase at all. Whereas the analogue 6a composed of epimeric α-valienamine residue did not possess any potency against both enzymes.


Clinical & Experimental Metastasis | 1993

Expression of ganglioside GM3 and H-2 antigens in clones with different metastatic and growth potentials isolated from Lewis lung carcinoma (3LL) cell line

Jin-ichi Inokuchi; Masayuki Jimbo; Yukihiro Kumamoto; Hiroshi Shimeno; Atsuo Nagamatsu

In view of the evidence that cell expression of gangliosides in several tumors is positively involved in the metastatic phenotype, Lewis lung carcinoma (3LL) cell line, expressing GM3 as the major ganglioside, was analysed for the cell surface expression of GM3. An indirect immunofluorescence assay, using a M2590 monoclonal antibody recognizing GM3, was used for this purpose. Since the parental 3LL cells consist of heterogenous subpopulations differing in the degrees of GM3 expression, we have developed clones of this cell line with different degrees of metastatic potentials by using anin vitro non-selective procedure in order to investigate whether the expression of GM3 is associated with metastatic potential. The degree of cell surface expression of GM3 among the clones correlated well with their total cellular content of this ganglioside. However, we were unable to confirm the report of increased level of GM3 in high metastatic 3LL clones, nor did a decreased level correlate with weak metastatic ability. In our recent work, an inhibitor of glucosylceramide synthase,d-threo-l-phenyl-2-decanoylamino-3-morpholino-l-propanol (DPDMP), was found to decrease the levels of all cellular glucosphingolipids and cause the accumulation of the precursors of glucosylceramide. The present study does not, however, rule out the possible involvement of this lipid family in metastatic dissemination, since treatment of 3LL cells with D-PDMP resulted in significant inhibition of their experimental metastatic potential. Clones expressing very low GM3 grew slowly in culture dishes, suggesting that GM3 may have a regulatory role in cell proliferation. The low metastatic clones expressed high levels of H-2Kb antigen, while the expression of the same antigen on the high metastatic clones was relatively low, confirming the previous observation of this tumor system. Moreover, a clone showing the lowest tumorigenic potency revealed both a high cell surface expression of H-2Kb and a high H-2Kb/H-2Db ratio.


FEBS Letters | 1991

Sphingosine inhibits attachment of murine Lewis lung carcinoma cells to laminin and type IV collagen

Jin-ichi Inokuchi; Yukihiro Kumamoto; Masayuki Jimbo; Hiroshi Shimeno; Atsuo Nagamatsu

The effect of sphingosine (SPH) on the adhesive properties of Lewis lung carcinoma (3LL) cells was investigated using plastic precoated with the extracellular matrix proteins, laminin, fibronectin, or type IV collagen. Treatment of 3LL cells with SPH (0.5–10 μM) resulted in a dose‐dependent decrease in the ability to bind to laminin and type IV collagen but had little or no effect on atachment to fibronectin. Phorbol 12‐myristate 13‐acetate (PMA) selectively enhanced attachment of 3LL cells to laminin and collagen. The inhibitory effect of SPH on attachment to both proteins was competitively antagonized by PMA. These results suggest that SPH acts as a negative effector for cell attachment to laminin and collagen, and that the cell attachment process to both proteins might be regulated in part by protein kinase C.


Cancer Research | 1990

Inhibition of Experimental Metastasis of Murine Lewis Lung Carcinoma by an Inhibitor of Glucosylceramide Synthase and Its Possible Mechanism of Action

Jin-ichi Inokuchi; Masayuki Jimbo; Keiko Momosaki; Hiroshi Shimeno; Atsuo Nagamatsu; Norman S. Radin


Journal of Biochemistry | 1992

Improved Inhibitors of Glucosylceramide Synthase.

Akira Abe; Jin-ichi Inokuchi; Masayuki Jimbo; Hiroshi Shimeno; Atsuo Nagamatsu; James A. Shayman; Girja S. Shukla; Norman S. Radin


Biochemical and Biophysical Research Communications | 1997

Up-regulation of ganglioside biosynthesis, functional synapse formation, and memory retention by a synthetic ceramide analog (L-PDMP).

Jin-ichi Inokuchi; Akihiro Mizutani; Masayuki Jimbo; Seigou Usuki; Kiwamu Yamagishi; Hideo Mochizuki; Kazuyo Muramoto; Kazuo Kobayashi; Yoichiro Kuroda; Katsunori Iwasaki; Yusuke Ohgami; Michihiro Fujiwara


Journal of Biochemistry | 1995

Stimulation of glycosphingolipid biosynthesis by L-threo-1-phenyl-2-decanoylamino-1-propanol and its homologs in B16 melanoma cells.

Jin-ichi Inokuchi; Seigou Usuki; Masayuki Jimbo

Collaboration


Dive into the Masayuki Jimbo's collaboration.

Top Co-Authors

Avatar

Jin-ichi Inokuchi

Tohoku Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge